Skip to main content
. 2021 Jul 29;21(3):273–283. doi: 10.1007/s40268-021-00357-0

Fig. 6.

Fig. 6

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and host angiotensin-converting enzyme 2 (ACE2) receptor interaction and mechanism of virus entry (left panel). A novel therapeutic peptide 13-amino acid peptide inhibitor (13AApi) blocks the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein from interacting with the host cell surface ACE2 (right panel). The 13AApi is a promising therapeutic candidate to prevent virus entry and infection in the host. The image was created with BioRender